Advertisement
Viatris Announces US Commercial Launch Of RYZUMVl 0.75%
(RTTNews) - Healthcare company Viatris Inc. (VTRS) announced Monday the U.S. commercial launch of RYZUMVI (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the U.S.
RYZUMVI is now the only U.S. commercially available FDA-approved eye drop to reverse dilation.
Comprehensive dilated eye exams play a vital role in detecting potential vision-impairing ophthalmic conditions such as cataracts and potentially blinding diseases like glaucoma, diabetic retinopathy, and age-related macular degeneration.
The U.S. Food and Drug Administration (FDA) approved RYZUMVI in September 2023.
read more
Viatris Guides FY24 In Line With Estimates - Update
While reporting financial results for the fourth quarter on Wednesday, healthcare company Viatris Inc. (VTRS) initiated its adjusted earnings and revenue guidance for the full-year 2024.
RTTNews
|
428 days ago
Viatris Reaffirms FY23 Revenue Outlook, Declares Dividend - Update
While reporting financial results for the second quarter on Monday, healthcare company Viatris Inc. (VTRS) reaffirmed its total revenue guidance for the full-year 2023.
RTTNews
|
633 days ago
Viatris Reaffirms FY23 Revenue Outlook, Declares Dividend - Update
While reporting financial results for the first quarter on Monday, healthcare company Viatris Inc. (VTRS) reaffirmed its total revenue guidance for the full-year 2023.
RTTNews
|
724 days ago
Viatris To Acquire Oyster Point And Famy Life Sciences To Create Ophthalmology Franchise
Healthcare company Viatris Inc. (VTRS) announced Monday that it intends to create an ophthalmology franchise by acquiring Oyster Point Pharma and Famy Life Sciences.
RTTNews
|
906 days ago
Viatris Reaffirms FY22 Revenue Outlook, Declares Dividend - Update
While reporting financial results for the third quarter on Monday, healthcare company Viatris Inc. (VTRS) reaffirmed its total revenue guidance for the full-year 2022 to solid operating momentum despite foreign exchange headwinds and absorbing inflation impact to date.
RTTNews
|
906 days ago
U.S. District Court Rules In Favor Of Merck In Patent Infringement Suit Against Viatris
Merck (MRK), known as MSD outside of the United States and Canada, announced Thursday that the U.S. District Court for the Northern District of West Virginia ruled in favor of the company in a patent infringement suit against Viatris, Inc. (VTRS) related to sitagliptin, an active ingredient in JANUVIA, JANUMET and JANUMET XR.
RTTNews
|
952 days ago
Viatris Trims FY22 Revenue Outlook, Declares Dividend - Update
While reporting financial results for the second quarter on Monday, healthcare company Viatris Inc. (VTRS) trimmed its total revenue guidance for the full-year 2022 to reflect the incremental impact of foreign exchange.
RTTNews
|
997 days ago
Australian Market Extends Early Gains In Mid-market
The Australian stock market is extending its early gains in mid-market moves on Friday, adding to the gains in the previous six sessions, following the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is moving a tad above the 8,200 level, with gains in iron ore miners, financial and energy stocks partially offset by weakness in gold miners and technology stocks.
RTTNews
|
57 minutes ago
